Clinical Trial Update: Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

A phase II study evaluating ASLAN001 in combination with capecitabine for CNS metastases in HER2-positive breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ASLAN001
• Capecitabine (capecitabine)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: TERMINATED